Mn Services Vermogensbeheer B.V. Purchases 37,611 Shares of Pfizer Inc. $PFE

Mn Services Vermogensbeheer B.V. boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 1.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,196,611 shares of the biopharmaceutical company’s stock after acquiring an additional 37,611 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Pfizer were worth $54,696,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. State Street Corp grew its stake in shares of Pfizer by 0.9% during the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after purchasing an additional 2,786,098 shares during the period. Northern Trust Corp lifted its stake in shares of Pfizer by 1.4% in the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after purchasing an additional 869,175 shares during the period. Fisher Asset Management LLC lifted its stake in shares of Pfizer by 1.9% in the 3rd quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock worth $1,255,860,000 after purchasing an additional 897,786 shares during the period. Legal & General Group Plc boosted its holdings in shares of Pfizer by 8.6% in the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after buying an additional 3,296,415 shares during the last quarter. Finally, Amundi grew its position in Pfizer by 10.8% during the third quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock valued at $1,096,380,000 after buying an additional 4,043,413 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on PFE shares. Royal Bank Of Canada started coverage on shares of Pfizer in a report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 target price for the company. Barclays initiated coverage on shares of Pfizer in a research note on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target on the stock. TD Cowen restated a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. Finally, HSBC lifted their target price on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.19.

Pfizer Price Performance

Shares of NYSE:PFE opened at $27.75 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The company has a market capitalization of $157.80 billion, a P/E ratio of 20.41 and a beta of 0.47. The firm’s 50 day simple moving average is $26.88 and its two-hundred day simple moving average is $25.72.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.63 earnings per share. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Market optimism around Pfizer’s once‑monthly GLP‑1/weight‑loss candidate and coverage by high‑profile commentators has driven short‑term buying interest — investors are revisiting Pfizer’s positioning in the obesity/GLP‑1 market. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Longer‑term bullish commentary and retail coverage argue Pfizer’s diversified portfolio, pipeline and ability to pivot (including GLP‑1 work) make it an attractive buy for patient investors. This kind of coverage can sustain inflows beyond short‑term headlines. Prediction: Buying Pfizer Stock Today Could Set You Up for Life
• Positive Sentiment: Inclusion on lists of large‑cap stocks with high dividends highlights Pfizer’s income appeal; dividend support can attract conservative and yield‑seeking investors amid growth uncertainty. Pfizer (PFE) – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Spike in search and retail attention (tracked by Zacks) signals higher visibility and trading volume; increased attention can amplify moves in either direction depending on upcoming catalysts. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Consensus analyst rating remains a “Hold” (mixed buy/hold/sell split), reflecting balanced views on near‑term growth vs. pipeline uncertainty — this limits the likelihood of broad upgrades unless clinical or commercial news surprises to the upside. Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of “Hold” from Analysts
• Negative Sentiment: Competitive moves from rivals — notably Eli Lilly’s large AI‑enabled drug discovery deal — underline accelerating competition and faster innovation cycles in diabetes/weight‑loss and other areas, a risk to Pfizer’s market share and margin outlook over time. Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.